학술논문
A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Document Type
Article
Author
Source
In Annals of Oncology May 2008 19(5):977-983
Subject
Language
ISSN
0923-7534